Nereus Pharmaceuticals Closes Second Tranche Funding

San Diego-based Nereus Pharmaceuticals is reporting this morning that it has closed the second tranche of its Series D preferred stock funding. The firm said that it received $18.3M of the previously reported $42.6M in funding, and disclosing that the original close of the funding in December of 2004 was worth $24.3M. Lead investors in the tranche were HBM BioVentures Ltd. and HBM BioCapital LP, and the round included participation by Alta Partners, Forward Ventures, Pacific Venture Group, Novartis Bioventure Fund, Genavent, and its other prior investors. The company has now raised $80.6M for its development of treatments for tumors and cancer. More information »